Matches 51 - 100 out of 443 < 1 2 3 4 5 6 7 8 9 >
Match Document Document Title
7431927 TNFα-neutralizing antibodies  
The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from...
7432360 Multi-dose erythropoietin formulations  
The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium...
7427471 Modified “S” antibodies  
The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the...
7425330 Methods of inhibiting TNFα activity in the blood of a patient  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7423129 Antibodies to human eotaxin  
The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or...
7416729 Methods of treating rheumatoid arthritis with anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7411049 Hybridoma cell lines and monoclonal antibodies recognizing Prox1  
Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays...
7405277 Antibodies against monocyte chemotactic proteins  
The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the...
7405274 Connective tissue growth factor antibodies  
The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention...
7404955 Methods of inhibiting or neutralizing TNFα in patients with tissue injury  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7402662 Antibody molecules specific to human tumor necrosis factor alpha  
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein...
7396911 Chimeric polypeptides containing chemokine domains  
This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses...
7390491 Agents comprising midkine or an inhibitor thereof as active ingredient  
Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
7390490 Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine  
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there...
7387776 Human monoclonal antibodies against CD30  
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
7381801 Chimerized GM-CSF antibodies  
Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically...
7371825 Anti-MCP-1 antibodies, compositions, methods and uses  
The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic...
7371377 Antibodies to polypeptides homologous to VEGF and BMP1  
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
7371383 Recombinant anti-interleukin-9 antibodies  
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat...
7368111 Human antibodies specific for TGFβ2  
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
7364865 Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)  
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3...
7361474 Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer  
The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an...
7354584 Recombinant IL-9 antibodies  
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and...
7355014 Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use  
A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active...
7342110 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same  
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
7329737 Antibodies that bind hK-1  
The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
7317089 Antagonistic anti-hTNFSF13b human antibodies  
Human monoclonal antibodies that specifically bind to TNFSF13 b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13 b (e.g., K D =10 −8 M or less), a slow off rate for...
7314722 Cytostatin II antibodies and methods  
The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the...
7312320 Neutralizing antibodies and methods of use thereof  
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not...
7307152 Secreted and transmembrane polypeptides and nucleic acids encoding the same  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7300916 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases  
A pharmaceutical preparation for preventing and/or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More...
7288250 Monoclonal antibodies against HMGB1  
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting...
7285642 Composition and method for modulating dendritic cell-T cell interaction  
The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing,...
7285269 Antibodies directed to tumor necrosis factor  
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid...
7279559 Antibodies that bind to interleukin-22  
Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
7276239 Recombinant A2-specific TNFα-specific antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7273609 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L  
The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of...
7270816 IL-1-like cytokine antibodies  
Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided....
7265211 Anti-IL-TIF antibodies and methods of making  
The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes...
7264801 EG-VEGF nucleic acids and polypeptides and method of use  
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells...
7261893 Neutralizing antibodies against GDF-8 and uses therefor  
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in...
7259244 Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same  
The present invention provides a human polypeptide homolog of DBF4/ASK1 (for “Activator of S phase kinase”) and polynucleotides which identify and encode DRF1 (for “DBF4 Related Factor 1”)....
7253264 Immunoglobulin fusion proteins, their production and use  
The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the...
7253265 Antibody and a method for producing an antibody that specifically binds to a full length amino acid sequence of human Delta-1  
An antibody and a method for producing an antibody that specifically binds to a full length amino acid sequence of human Delta-1.
7250276 Human IL-1 epsilon DNA and polypeptides  
The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such...
7250165 Anti-TNF antibodies, compositions, methods and uses  
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or...
7247711 IL-23p40 specific antibody  
Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived...
7241576 Uses of THANK, a TNF homologue that activates apoptosis  
The present invention is directed to the applications of a novel cytokine, named THANK, for TNF homologue that activates apoptosis, NF-κB and c-jun N-terminal kinase. Such applications include...
7226593 Methods of treating cachexia with chimeric anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α(TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7227003 Anti-TNF antibody fragments  
Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as...
Matches 51 - 100 out of 443 < 1 2 3 4 5 6 7 8 9 >